An ActRIIA fusion protein got FDA approved for PAH treatment
Mar 28 2024Reviewed by Maria Osipova On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment. PAH, characterized…